GHE 16/12/2010



A CASE STUDY:
TRIANGULAR COOPERATION
BETWEEN ARGENTINA AND SPAIN
ON NEGLECTED TROPICAL DISEASES (NTDs)

NIDs

NTDs blight the lives of at least 1 billion of the poorest people in the world

NTDs are turning into an emergent risk for the worldwide population, due mainly to new changing patterns on climate and immigration.

























NIDs

Decreasing NTDs prevalence figures show there has been a **paradigm shift** meanly due to change in focus from diseases to **population needs**

The first WHO report on neglected tropical diseases (NTDs) 2010: working to overcome the global impact of NTDs.





























GLOBAL CONTEXT

Period of crises...

- Financial crises
- Decreasing amount and number of donors
- People skepticism, case of Haití
- New immigration patterns
- Climate Change

...period of opportunities!

























TRIANGULAR COOPERATION

Correct managing of resources from different partners, including "new donors", brings:

- ✓ more efficient use of resources,
- √ better coordination between partners/donors
- ✓ reduces unnecessary parallelism and competition

























TRIANGULAR COOPERATION

Seen as <u>technical cooperation</u> through an association of resources (not only financial) with a partner in a semi-developed country, with know-how, structure, legitimacy, and maturity to manage and provide horizontal cooperation.

























We are different:

- ✓ Headquarters in the "south"
- ✓ Staff of more than 50 qualified people
- ✓ Labs in 5 endemic hotspots
- ✓ Working in a technical field
- ✓ Professional management (1 vs 6 euros/beneficiary)

















































































































































































Some of our projects:

- Since 2002. "House improvements for **Chagas** disease prevention in Añatuya". Regional Health System/Mundosano.
- Since 2007. "Tele-epidemiology project. Use of geographic information system for surveillance and elaboration of risk maps". Puerto Iguazú, Clorinda and Tartagal.
- •2009. Public/private partnership on **Dengue** control at Tartagal.
- •2010. Global Network for Neglected Tropical Diseases/Sabine Vaccine Institute (CDC), Instituto de Investigación de Enfermedades Tropicales de la Universidad Nacional de Salta, on **Strongyloides** prevention and treatment.



























AND NOW... We "move on" to the "north", growing with the partnership with Mundo Sano España (a foundation from the pharmaceutical generic industry – CHEMO group)































Mundo Sano España



- ✓ Seeking for new partners (north and south)
- ✓ Creating awareness
- ✓ Offering our expertise and facilities
- ✓ Wanting to learn and cooperate















































































































A scientific and technical cooperation platform
working as
field laboratory of experiences for NTDs



























To create "models of intervention" for:

✓ National Health Services

✓ International Health Agencies

























WORKING ON POPULATION NEEDS

Being part of the community

✓ Without rising false expectations

Creating sinergies among partners

- ✓ We acknoledge the importance of all actors involved in NTDs (public, private, CSOs, scientific, media,...)
- ✓ We articulate public/private partnerships































AND CREATING AWARENESS

Promoting awareness and knowledge:

- ✓ From Scientist to Immigrants
- ✓ In the south, XIII Simposio on NTDs in Argentina, and in the north, VII Workshops of Chagas disease in Spain



























TO TRANSFORM THEIR REALITY

✓ Guaranty a long term predictable and effective support with no distortions to the NTDs'endemic populations

























THANK YOU FOR YOUR ATTENTION

COMMENTS ARE WELLCOME, PLEASE ADDRESS TO:

Juanjo Santos jsantos@mundosano.org





























This paper was produced for a meeting organized by Health & Consumers DG and represents the views of its author on the subject. These views have not been adopted or in any way approved by the Commission and should not be relied upon as a statement of the Commission's or Health & Consumers DG's views. The European Commission does not guarantee the accuracy of the data included in this paper, nor does it accept responsibility for any use made thereof.